ClinicalTrials.gg
Not yet recruitingNCT07940465Updated Nov 16, 2026

PENG Block Versus Epidural Block for Postoperative Analgesia After Total Hip Arthroplasty

An interventional study of Epidural Block and Pericapsular Nerve Group Block (PENG Block) in Total Hip Arthroplasty (THA) and Postoperative Pain Management, sponsored by Bangladesh Medical University. Not yet recruiting at 1 site in Bangladesh. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Bangladesh Medical University · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This study aims to compare the effectiveness of ultrasound-guided Pericapsular Nerve Group (PENG) block and epidural block for postoperative analgesia in patients undergoing elective unilateral total hip arthroplasty. A total of 62 eligible patients will be randomly allocated into two groups: Group A will receive epidural block, and Group B will receive PENG block. Postoperative pain scores, opioid consumption, time to first rescue analgesia, motor blockade, adverse effects, and time to mobilization will be assessed to compare the analgesic efficacy and recovery outcomes of the two techniques.

Read the detailed description

Postoperative pain management is an important component of recovery following total hip arthroplasty. Epidural analgesia is an established regional anesthesia technique, whereas ultrasound-guided Pericapsular Nerve Group (PENG) block is a newer technique intended to provide targeted analgesia to the hip joint.

This single-blind, randomized controlled trial will compare these two techniques in 62 patients undergoing elective unilateral total hip arthroplasty at Bangladesh Medical University, Dhaka, Bangladesh.

Participants will be randomly assigned in a 1:1 ratio to receive either an epidural block or a PENG block. Both groups will receive standardized postoperative multimodal analgesia. Pain intensity will be assessed using the Numeric Rating Scale (NRS) at 0, 2, 4, 6, 12 and 24 hours after surgery. Additional outcomes will include total opioid consumption, time to first rescue analgesia, motor blockade, adverse effects, and time to mobilization.

The findings will help compare the analgesic effectiveness and postoperative recovery associated with these two regional anesthesia techniques.

02

Conditions studied

  • Total Hip Arthroplasty (THA)
  • Postoperative Pain Management

Browse trials for

Keywords

  • Epidural Analgesia
  • Pericapsular Nerve Group Block
  • Postoperative Pain Management
  • Total Hip Arthroplasty
03

In context

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

This study's planned enrollment of 62 is below the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Bangladesh Medical University is the lead sponsor of 45 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18- 64 years, either sex
  • Gender: Male and Female
  • : I, II, or III
  • Patients undergoing elective unilateral total hip arthroplasty
  • Written obtained

Exclusion criteria

Exclusion Criteria:

  • Patient refusal to participate
  • Known allergy to local anesthetics
  • Infection at block site
  • Coagulopathy ( >1.5, \<100,000/mm³)
  • Neurological deficits in operated limb
  • Chronic opioid use
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
62 participants (estimated)

Study arms

  • Active comparator
    Group A

    Participants will receive an epidural block before spinal anaesthesia using an 18G Tuohy needle at L2-L3 or L3-L4, followed by a test dose with 3 mL of 2% lidocaine with adrenaline and 15-20 mL of 0.25% bupivacaine.

    Procedure: Epidural Block

  • Experimental
    Group B

    Participants will receive an ultrasound-guided PENG block in the supine position before spinal anaesthesia, using a 22-gauge needle and 20 mL of 0.25% bupivacaine.

    Procedure: Pericapsular Nerve Group Block (PENG Block)

Interventions

  • ProcedureEpidural Block

    Participants will receive an epidural block before spinal anaesthesia using an 18G Tuohy needle at L2-L3 or L3-L4, followed by a test dose and 15-20 mL of 0.25% bupivacaine.

  • ProcedurePericapsular Nerve Group Block (PENG Block)

    Participants will receive an ultrasound-guided Pericapsular Nerve Group Block (PENG) block before induction in the supine position, using a 22G needle and 20 mL of 0.25% bupivacaine.

06

What researchers measure

Primary outcomes

  1. Postoperative pain score at rest and on movement using the Numeric Rating Scale (NRS)

    Pain intensity will be assessed using a 10-cm Numeric Rating Scale (NRS). The scale ranges from 0 to 10 cm, where 0 cm indicates no pain and 10 cm indicates the worst imaginable pain. Higher scores indicate greater pain intensity.

    Time frame: At the recovery room- 0, 2, 4, 6, 12 and 24 hours after surgery

Secondary outcomes

  1. Time to First Rescue Analgesia

    Time from completion of surgery to the first administration of rescue analgesia (intravenous morphine 0.05 mg/kg when the Numeric Rating Scale pain score is 4 or higher). The time will be recorded in minutes.

    Time frame: Within 24 hours after surgery

  2. Total Opioid Consumption

    Total amount of intravenous morphine administered as rescue analgesia to each participant during the first 24 hours after surgery, measured in milligrams (mg).T

    Time frame: Time Frame: First 24 hours after surgery.

  3. Postoperative Motor Blockade

    Motor blockade will be assessed using the Modified Bromage Scale, ranging from 0 to 3. A score of 0 indicates no motor block, while a score of 3 indicates complete motor block with inability to move the hip, knee, and ankle. Higher scores indicate greater motor blockade.

    Time frame: At the recovery room- 0, 2, 6 hours after surgery

  4. Postoperative Adverse Effects

    Description: The occurrence of postoperative adverse effects, including hypotension, nausea, vomiting, and urinary retention, will be recorded for each participant. Each adverse effect will be documented as present or absent.

    Time frame: First 24 hours after surgery

  5. Time to First Mobilization

    Time from surgery completion until the participant first stands or walks. The time will be recorded in minutes.

    Time frame: Within 24 hours after surgery

07

Study locations

1 site
08

References and documents

Publications

  • Staikou C, Rekatsina M, Leoni MLG, Chamos C, Kapsokalyvas I, Varrassi G, Karmaniolou I. Efficacy and Safety of Pericapsular Nerve Group Block (PENG) in Hip Surgery Under General Anaesthesia: A Systematic Literature Review and Meta-Analysis. J Clin Med. 2025 Jan 13;14(2):468. doi: 10.3390/jcm14020468. PubMed 39860473 ↗
  • Sloan M, Premkumar A, Sheth NP. Projected Volume of Primary Total Joint Arthroplasty in the U.S., 2014 to 2030. J Bone Joint Surg Am. 2018 Sep 5;100(17):1455-1460. doi: 10.2106/JBJS.17.01617. PubMed 30180053 ↗
  • Reysner T, Kowalski G, Mularski A, Reysner M, Wieczorowska-Tobis K. From Pain Control to Early Mobility: The Evolution of Regional Anesthesia in Geriatric Total Hip Arthroplasty. Reports (MDPI). 2025 May 9;8(2):64. doi: 10.3390/reports8020064. PubMed 40710855 ↗
  • Pires Sousa I, Leite da Silva Peixoto CI, Fernandes Coimbra LA, da Costa Rodrigues FM. Comparison of pericapsular nerve group (PENG) block and epidural analgesia following total hip arthroplasty: A retrospective analysis. Rev Esp Anestesiol Reanim (Engl Ed). 2022 Dec;69(10):632-639. doi: 10.1016/j.redare.2022.10.002. Epub 2022 Nov 12. PubMed 36376187 ↗
  • Pascarella G, Costa F, Del Buono R, Pulitano R, Strumia A, Piliego C, De Quattro E, Cataldo R, Agro FE, Carassiti M; collaborators. Impact of the pericapsular nerve group (PENG) block on postoperative analgesia and functional recovery following total hip arthroplasty: a randomised, observer-masked, controlled trial. Anaesthesia. 2021 Nov;76(11):1492-1498. doi: 10.1111/anae.15536. Epub 2021 Jul 1. PubMed 34196965 ↗
  • Pai P, Amor D, Lai YH, Echevarria GC. Use and Clinical Relevancy of Pericapsular Nerve Block (PENG) in Total Hip Arthroplasty: A Systematic Review and Meta-analysis. Clin J Pain. 2024 May 1;40(5):320-332. doi: 10.1097/AJP.0000000000001196. PubMed 38268183 ↗
  • Lee KH, Wang JC, Chang CY, Teng WN, Wang HY, Lee CC, Tsai SW, Chen CF, Wu PK, Chen WM. Regional anaesthesia modalities for primary total hip arthroplasty: a systematic review and component network meta-analysis. Br J Anaesth. 2025 Aug;135(2):469-482. doi: 10.1016/j.bja.2025.04.019. Epub 2025 Jun 6. PubMed 40483183 ↗
  • Kehlet H. Fast-track hip and knee arthroplasty. Lancet. 2013 May 11;381(9878):1600-2. doi: 10.1016/S0140-6736(13)61003-X. No abstract available. PubMed 23663938 ↗
  • Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S240-52. doi: 10.1002/acr.20543. No abstract available. PubMed 22588748 ↗
  • Giron-Arango L, Peng PWH, Chin KJ, Brull R, Perlas A. Pericapsular Nerve Group (PENG) Block for Hip Fracture. Reg Anesth Pain Med. 2018 Nov;43(8):859-863. doi: 10.1097/AAP.0000000000000847. PubMed 30063657 ↗
  • Evangelista T, Pugno C, Finazzi S, Colombi A, Bugada D. Regional anesthesia for hip surgery: A review of current approaches and their application to clinical practice. Saudi J Anaesth. 2025 Apr-Jun;19(2):164-173. doi: 10.4103/sja.sja_68_25. Epub 2025 Mar 25. PubMed 40255351 ↗
  • de Souza DN, Lorentz NA, Charalambous L, Galetta M, Petrilli C, Rozell JC. Comprehensive Pain Management in Total Joint Arthroplasty: A Review of Contemporary Approaches. J Clin Med. 2024 Nov 13;13(22):6819. doi: 10.3390/jcm13226819. PubMed 39597962 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for May 2027, 5 months later.

Of 2,097 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 5 months is below that.

Counting every sponsor, half of 2,110 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 16, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940465
Lead sponsor
Bangladesh Medical University
Responsible party
Mohammad Shafiqul Islam (Professor, Bangladesh Medical University) — Principal investigator
First posted
Nov 16, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Kazi Mahzabin Arin, MD
Contact
kazimahzabinarin@bmu.ac.bd
01754057689

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion